- Topical finasteride is the same licensed active compound as oral finasteride, reformulated for application to the scalp.
- A 2018 randomised trial and a 2021 phase III trial found scalp DHT suppression comparable to oral 1 mg with lower, but not zero, systemic exposure.
- Serum DHT still fell by roughly 30 to 40 percent with the topical spray. It is not a purely local compound.
- In the UK it is prescription only, supplied as an unlicensed special through private clinics. It is not sold over the counter, and not by us.
- RU-58841 and pyrilutamide are a different category: receptor antagonists, research use only, no prescription pathway.
What topical finasteride is
Finasteride is a 5-alpha-reductase inhibitor. It blocks the type II isoform of the enzyme that converts testosterone into dihydrotestosterone, DHT, the androgen that drives follicle miniaturisation in genetically susceptible scalps. As an oral 1 mg tablet it has been a licensed medicine for male pattern hair loss since the late 1990s, with a large and consistent evidence base behind it.
Topical finasteride is the same molecule delivered a different way. Instead of a tablet, the drug is dissolved in a solution, gel, or spray and applied to the scalp. The logic is straightforward: the enzyme finasteride inhibits is present in the scalp itself, so if enough drug can be delivered locally, scalp DHT might be suppressed with less drug reaching the rest of the body. Whether that logic holds is an empirical question, and topical finasteride is one of the few scalp topicals where it has actually been tested in properly controlled trials.
The clinical evidence, honestly summarised
The 2018 randomised trial
A randomised, double-blind trial published in 2018 compared a topical finasteride 0.25% solution against oral finasteride in men with androgenetic alopecia. Both routes increased hair counts over the study period, with no significant difference between them, and both suppressed scalp DHT to a similar degree. The notable finding was pharmacokinetic: the topical route produced markedly lower plasma finasteride levels than the tablet, while serum DHT still fell in both groups. The trial was small and relatively short, which is worth keeping in view, but its direction of findings set up the larger programme that followed.
The 2021 phase III trial
The larger test came with a phase III randomised, double-blind, placebo-controlled trial published in 2021, evaluating a topical finasteride 0.25% spray applied once daily against both placebo and oral finasteride 1 mg. Over 24 weeks, the topical spray increased target area hair count significantly versus placebo, with a change from baseline that was numerically similar to the oral arm. On the exposure side, the numbers are the interesting part. Mean plasma finasteride exposure with the spray was a small fraction of that seen with the tablet, more than 100 times lower. Serum DHT, however, still fell by roughly a third from baseline in the topical group, against reductions in the region of half or more typically reported for oral 1 mg.
Read plainly, the trial supports two conclusions at once. Topical delivery does what it was designed to do: it shifts the exposure profile toward the scalp and away from the circulation. And it does not make finasteride a locally confined compound. A 30 to 40 percent reduction in circulating DHT is a systemic effect by any reasonable definition, smaller than the oral tablet's but clearly present. Anyone describing topical finasteride as having no systemic activity is overstating what the data show.
What the evidence does not yet cover
The controlled data run to months, not years, and long-term comparative outcomes between topical and oral routes remain thin. Whether the lower systemic exposure translates into a meaningfully different side effect profile over time is a hypothesis the pharmacokinetics make plausible but the trials were not sized or extended to prove. That question belongs to future studies and to the clinicians who prescribe the drug, and it is worth being suspicious of anyone who claims it is already settled.
UK availability and legal status
In the UK, finasteride is a prescription-only medicine in every formulation. The licensed products are oral tablets. Topical finasteride has no UK marketing authorisation, which means it is supplied, where it is supplied at all, as an unlicensed special: a formulation compounded by a pharmacy against a private prescription written by a doctor who takes responsibility for that prescribing decision. In practice this happens through private hair loss clinics, Belgravia Centre being a well-known example, and through some online prescribing services. It is not sold over the counter, it is not available from retailers, and any site offering finasteride without a prescription is operating outside UK medicines law.
To be direct about our own position: Norwood Labs does not sell finasteride in any form, topical or oral, and nothing in this article is a recommendation to seek it out or a substitute for medical advice. Questions about whether topical finasteride is appropriate for a given person are prescribing questions, and they belong with a clinician.
A different mechanism: reducing DHT versus blocking its receptor
Topical finasteride often gets grouped with research antiandrogens because everything ends up on the same scalp, but mechanistically they sit on opposite sides of the pathway. Finasteride acts upstream: it reduces the amount of DHT that gets made. An androgen receptor antagonist acts downstream: it leaves DHT levels alone and competes with DHT for the receptor itself, so the androgen has nowhere to dock. We cover this distinction in detail in our guide to topical DHT blockers, but the short version is that "applied to the scalp" describes a delivery route, not a mechanism, and the two strategies are not interchangeable.
The distinction has a practical consequence for interpretation. Because finasteride lowers DHT production, its systemic footprint can be tracked with a blood test, which is exactly what the trials above did. A receptor antagonist can be systemically absorbed without moving DHT levels at all, so its systemic exposure has to be characterised differently, and for most research antiandrogens that characterisation is incomplete.
Where the research antiandrogens actually sit
RU-58841 and pyrilutamide (KX-826) are the two topical androgen receptor antagonists we supply, and honesty about their status matters more than flattering comparisons. Neither is a medicine. Neither has a UK licence, a prescription pathway, or the kind of completed phase III evidence described above. RU-58841's development was abandoned before any modern clinical programme completed, so its human evidence base is thin. Pyrilutamide has progressed through modern clinical trials in China, which makes it the better-evidenced of the two, but it remains unapproved everywhere and its pivotal results are not fully published. We compare the two directly in RU-58841 vs pyrilutamide.
A side-by-side summary of the categories:
| Topical finasteride | Research antiandrogens (RU-58841, KX-826) | |
|---|---|---|
| Mechanism | 5-alpha-reductase inhibition, reduces DHT production | Androgen receptor antagonism, blocks DHT binding |
| Human evidence | Randomised trials including a 2021 phase III | Limited; abandoned 1990s programme (RU-58841), ongoing unpublished trials (KX-826) |
| UK status | Prescription-only medicine, unlicensed special via private clinics | Unlicensed research compounds, research use only |
| Access route | Private prescription from a doctor | Sold as laboratory reference material, no prescription pathway exists |
| Systemic effect on DHT | Serum DHT reduced roughly 30 to 40% in trials | None expected by mechanism; systemic absorption not fully characterised |
The point of that table is not that one column beats the other. It is that they are not competitors in the same market. Topical finasteride is a medicine with real trial evidence and a doctor between it and the end user. The research antiandrogens are laboratory materials with a different mechanism and a much thinner evidence base, and pretending otherwise would be exactly the kind of grey-market marketing this site exists to avoid. For a fuller treatment of how the receptor antagonists compare with finasteride as a compound class, see RU-58841 vs finasteride.
The bottom line
Topical finasteride is one of the better-evidenced ideas in hair loss pharmacology of the last decade: same molecule, different route, with controlled trials showing scalp DHT suppression comparable to the oral tablet at a fraction of the plasma exposure, while still lowering circulating DHT by around a third. In the UK it remains a prescription-only medicine available as an unlicensed special through private clinics, and any decision about it belongs with a prescriber. Norwood Labs operates in a different category entirely: we supply RU-58841 and pyrilutamide as batch-assayed research compounds, each with a published certificate of analysis, strictly for laboratory research and not for human use.